Sector News

Shire starting on $400M biologics plant that will add 400 jobs

December 7, 2016
Life sciences

With approval from local officials in Ireland now in hand, Shire said work on a $400 million biologics plant can begin.

The rare disease drugmaker announced today that with the final planning step complete, it will begin recruiting for the 400 jobs the new plant is expected to require.

“We are pleased to have met this important milestone as we move forward in preparation to start building our new manufacturing plant,” Tim Kelly, Shire senior VP of biologics, said in a statement.

The construction on the facility, which will be able to produce clinical through commercial scale products, is expected to begin shortly and be complete in 2019. It is being built on a 120-acre site in Piercetown, County Meath, about 20 miles from Dublin.

Shire is a much larger company than it was when it announced the the plant last spring. In June it completed its $32 billion deal to acquire Baxalta. Now the company is in the process of merging Baxalta into its operations.

CEO Flemming Ornskov said in August that Shire now believes it can cut about $700 million in annual savings from the combined companies instead of the $500 million it initially promised investors. He said that about 20% will come from manufacturing as the company eliminates redundancies and finds ways to leverage the drugmakers’ combined scale of operations.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach